logo-loader
RNS
viewAstraZeneca

Publication of a Prospectus

/**/ em{letter-spacing:.5pt;border:none windowtext 1.0pt;padding:0cm;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bc{size:21.0cm 842.0pt;margin:3.0cm 72.0pt 0cm 72.0pt;}div.bc{}p.cl{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;line-height:normal}span.cj{font-weight:normal}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.ch{font-size:14.0pt;font-family:"Arial","sans-serif"}span.cf{font-size:12.0pt;font-family:"Arial","sans-serif"}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify}span.ce{color:black}span.cc{color:red} p.co{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.cb{font-size: 11.0pt;font-family:"Arial","sans-serif"}p.cp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.bz{font-size:11.0pt; font-family:"Arial","sans-serif"}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}span.bx{color: blue; text-decoration: underline}table.cr{width:435.25pt;margin-left:-5.4pt;border-collapse:collapse}tr.bq{height:21.15pt}td.bt{width:34.38%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt} p.cs{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;}span.bw{font-size:10.0pt}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; page-break-after: avoid; text-align: justify; text-indent: -5.5pt}td.bs{width:43.76%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}td.br{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}tr.bl{height:19.85pt}td.bo{width:34.38%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt}td.bn{width:43.76%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}td.bm{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt} td.bk{width:34.38%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.bj{width:43.76%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.bi{width:21.86%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}span.bh{font-size:10.0pt; color:black}p.cv{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-indent:-5.5pt;page-break-after: avoid}p.cw{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;text-autospace:none;vertical-align: middle}p.cx{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}span.bd{font-size: 10.0pt;font-family:"Arial","sans-serif"} /**/
RNS Number : 0175C
AstraZeneca PLC
12 June 2019
 

12 June 2019 16:45 BST

 

Publication of Prospectus

 

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:

 

Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

 

The last drawdown under the EMTN programme was in 2016.

 

To view the full document, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/0175C_1-2019-6-12.pdf

 

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

http://www.morningstar.co.uk/uk/NSM

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

 

Media Relations

 

 

Gonzalo Viña

 

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharma

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma (cardiovascular; metabolism)

+44 203 749 5711

Nick Stone

BioPharma (respiratory; renal)

+44 203 749 5716

Josie Afolabi

Other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free

 

+1 866 381 72 77

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
PDICKBDBPBKDQAD

Quick facts: AstraZeneca

Price: 7418

Market: LSE
Market Cap: £97.32 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE